• LAST PRICE
    1.4500
  • TODAY'S CHANGE (%)
    Trending Down-0.0700 (-4.6053%)
  • Bid / Lots
    1.4000/ 12
  • Ask / Lots
    1.5300/ 20
  • Open / Previous Close
    1.5200 / 1.5200
  • Day Range
    Low 1.4300
    High 1.5800
  • 52 Week Range
    Low 1.4000
    High 8.1500
  • Volume
    90,263
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.52
TimeVolumeBLCM
09:32 ET4501.53
09:33 ET1001.58
09:37 ET7501.4867
09:39 ET8001.56
09:46 ET1651.558
10:15 ET2001.52
10:49 ET11801.506
11:43 ET5901.52
11:56 ET3001.55
12:21 ET31001.52
12:39 ET10931.55
12:50 ET2641.525
01:06 ET2001.52
01:24 ET33451.54
01:27 ET11001.55
01:29 ET287411.5699
01:31 ET97231.5
01:33 ET2901.5195
01:36 ET10491.5
01:38 ET110581.47
01:42 ET131171.45
01:44 ET8001.46
01:45 ET11361.43
02:05 ET20471.43
02:07 ET1601.43
02:21 ET4001.43
02:27 ET1001.5199
02:41 ET8001.475
03:08 ET2001.5004
03:10 ET8001.5009
03:12 ET4001.5009
03:17 ET5001.4301
03:32 ET6821.48
03:42 ET10001.4757
03:44 ET8431.45
Data delayed at least 15 minutes.

Dec 28, 2021

8:15AM ET on Tuesday Dec 28, 2021 by MT Newswires
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBLCM
Bellicum Pharmaceuticals Inc
12.2M
1.2x
---
United StatesSNES
Senestech Inc
11.0M
-0.9x
---
United StatesXBIO
Xenetic Biosciences Inc
14.5M
-1.8x
---
United StatesQBIO
Q BioMed Inc
12.6M
-1.1x
---
United StatesTXTM
Protext Mobility Inc
12.6M
0.0x
---
United StatesPHIO
Phio Pharmaceuticals Corp
11.6M
-0.7x
---
As of 2022-01-22

Company Information

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. The Company's product candidates include BPX-601 and BPX-603. The BPX-601, is an autologous GoCAR-T product candidate containing iMC activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). The BPX-603, is a controllable dual-switch autologous GoCAR-T product candidate, which incorporates both the iMC activation switch and the CaspaCIDe safety switch.

Contact Information

Headquarters
3730 Kirby Drive, Suite 1200HOUSTON, TX, United States 77098
Phone
832-384-1100
Fax
302-655-5049

Executives

Independent Chairman of the Board
James Brown
President, Chief Executive Officer, Director
Richard Fair
Chief Development Officer
Charity Scripture
Independent Director
James Daly
Independent Director
Stephen Davis

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$12.2M
Revenue (TTM)
$6.2M
Shares Outstanding
8.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.37
EPS
$1.16
Book Value
$1.87
P/E Ratio
1.2x
Price/Sales (TTM)
2.0
Price/Cash Flow (TTM)
1.8x
Operating Margin
-526.87%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.